Riskpilot← Back to searchSign inGet full accessLife Science Consulting AE AB
ABActiveOrg 5592126410Rönngården 5Business and other management consultancy activities · NACE 7020Est. 20190 employees
Revenue 2024
SEK 1,5M
+2% vs 2023
EBITDA margin
43.9%
-9% vs 2023
Equity ratio
79.7%
Financial strength
Net profit 2024
SEK 373K
-8% vs 2023
| Revenue | SEK 1,5M | +2% |
| EBITDA | SEK 640K | -9% |
| Net profit | SEK 373K | -8% |
| Total assets | SEK 3,2M | +15% |
| Equity | SEK 2,6M | +17% |
| Employees | 0 | — |
Legal name
Life Science Consulting AE AB
Org number
5592126410
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
16 juli 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Ekblom, Anna Margareta
Company purpose
Bedriver verksamhet inom läkemedelsbranschen, life science och estetik.
Address
Rönngården 5
Email
ekblom.anna@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 656 | 1 263 | 959 | 1 426 | 1 457 |
| Staff expenses | — | — | −442 | −419 | −438 |
| EBITDA | 1 344 | 635 | 326 | 707 | 640 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 1 344 | 635 | 326 | 707 | 640 |
| Net financials | −2 | 11 | −52 | 0 | −89 |
| Profit before tax | 1 142 | 695 | 374 | 522 | 481 |
| Tax | −245 | −148 | −83 | −115 | −108 |
| Net profit | 897 | 547 | 290 | 407 | 373 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 420 | 2 042 | 2 105 | 2 805 | 3 218 |
| Equity | 947 | 1 494 | 1 785 | 2 192 | 2 565 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 273 | 398 | 270 | 379 | 348 |
| Total debt | 273 | 398 | 270 | 379 | 348 |
EBITDA margin
43.9%
This company
15.8%
Market median
+178% vs market
20202024
Equity ratio
79.7%
This company
38.2%
Market median
+109% vs market
20202024
Return on equity
14.5%
This company
18.4%
Market median
+21% vs market
20202024
Net profit margin
25.6%
This company
8.1%
Market median
+216% vs market
20202024
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
20202024
Debt / equity
0.25×
This company
0.62×
Market median
+60% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Life Science Consulting AE AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Fredrik Lennart Jansson | Deputy Board Member | 0 companies |
| Karin Margareta Henriksson | Deputy Board Member | 0 companies |
| Jimmy Michael Mellwing | Board of Directors | 0 companies |
| Anna Margareta Ekblom | Chairman | 0 companies |
| Sean Lorentz Maximilian Ekblom | Deputy Board Member | 0 companies |